Martin Gomez is a partner in Goodwin’s Technology Companies group specializing in intellectual property matters. Mr. Gomez focuses his practice on advising technology and life sciences companies of all sizes (including startups), and their investors, in corporate and especially intellectual property matters throughout the business life cycle, including new company formation, IP protection, fundraising, strategic transactions and exits.
Mr. Gomez is also a registered patent attorney. His practice includes intellectual property rights counseling, procurement, and enforcement, with significant experience in strategic patent portfolio development, transactional IP diligence, IP licensing, and patent and trade secret litigation. Mr. Gomez also has special expertise with design patents, both in obtaining design patent protection for clients and in evaluating design patent portfolios in the transactional and litigation contexts.
Mr. Gomez has a technical background in mechanical and biomedical engineering and has particular technical expertise in the areas of medical devices, laboratory testing / diagnostic equipment, and healthcare IT. He also regularly advises clients in other technology areas, including robotics, clean energy, consumer products, and computer-implemented / software-based technologies.
In addition to his practice before the U.S. Patent and Trademark Office, Mr. Gomez also has experience litigating patent and trade secret disputes before the federal courts. He has researched and drafted substantive motions / briefs, prepared expert reports, and participated in depositions and hearings concerning invalidity and non-infringement.
Mr. Gomez also maintains a robust pro bono practice. He assists local small businesses and entrepreneurs through Goodwin’s Neighborhood Business Initiative (NBI) and immigrant children through the Kids in Need of Defense (KIND) program. Mr. Gomez was the recipient of the 2019 Robert B. Fraser Pro Bono Award, given annually by the firm to one associate and one partner that have made significant contributions to the firm’s pro bono efforts.